By Euro Weekly News Media • 30 September 2014 • 16:44
SPANISH scientists have created a new drug which could cure half of breast cancer cases.
The experimental drug, called nintedanib, causes, in combination with standard chemotherapy with paclitaxel, a total remission of tumours in 50 per cent of patients with early breast cancer HER2-negative, the most common type of breast cancer types.
These are the findings of a first phase clinical trial sponsored by the National Cancer Research Centre (CNIO) through the Clinical Research Unit of Breast Cancer.
Miguel Angel Quintela, Head of the CNIO, said: “The combination of drugs has proved to be a success, since it has proven to be completely safe and yielded rates of complete cure of 50 per cent.” The trial included 10 patients with HER2-negative breast cancer, all in early stages of the disease.
In view of the results, the institution has already launched a large-scale clinical study for phase two to validate the work in a larger number of patients.
The results are expected in early 2015.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our
Share your story with us by emailing [email protected], by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
Your email address will not be published. Required fields are marked *
Download our media pack in either English or Spanish.